Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

4 trials match this view; 13 reported facilities; 13 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 258 across 4 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20231
20241
20262

Current indexed registry status

Recruiting2
Not yet recruiting1
Completed1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

4 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers

NCT05220046

Pancreas Cancer · Biliary Tract Cancer · Psychological Distress · Gastrointestinal Cancer
University of Nebraska

PHASE1

Completed

Registry updated 2026-08-19

18

ACTUAL

2023-04-10
2025-11-17
2025-11-17
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

NCT07063862

Psychological Distress
Bruyère Health Research Institute.

PHASE3

Recruiting

Registry updated 2026-07-10

120

ESTIMATED

2026-01-28
2027-08
2027-09
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial

NCT07791901

Advanced Cancer · Demoralization · Existential Distress · Psychological Distress
University of Calgary

PHASE2

Not yet recruiting

Registry updated 2026-09-02

60

ESTIMATED

2026-10-30
2027-12-20
2027-12-31

Reported research facilities

Arthur Child Comprehensive Cancer CentreCalgary, Alberta, Canada · Coordinates available
Bruyere HealthOttawa, Ontario, Canada · Coordinates available
McGill University Health CentreMontreal, Quebec, Canada · Coordinates available
Providence Care HospitalKingston, Ontario, Canada · Coordinates available
South Lake Regional Health CentreNewmarket, Ontario, Canada · Coordinates available
St. Joseph's HealthcareLondon, Ontario, Canada · Coordinates available
The Ottawa HospitalOttawa, Ontario, Canada · Coordinates available
William Osler Health SystemBrampton, Ontario, Canada · Coordinates available
Spital Uster AG, Division of Internal MedicineUster, Switzerland · Coordinates available
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland · Coordinates available
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland · Coordinates available
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland · Coordinates available
University of Nebraska Medical CenterOmaha, Nebraska, United States · Coordinates available

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.